IMVT
Immunovant, Inc.
NASDAQ · Healthcare · Biotechnology · US
$39.51
+1.00%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 7.1M | — | — | — | — |
| Cost of Revenue | 206.0K | 409.0K | — | — | — |
| Gross Profit | 6.9M | (409.0K) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 498.1M | 456.7M | 360.9M | 212.9M | 160.3M |
| SG&A Expense | 67.9M | 76.2M | 77.2M | 57.3M | 48.0M |
| General & Admin Expense | 67.9M | 76.2M | 77.2M | 57.3M | 48.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 566.0M | 532.9M | 438.2M | 270.2M | 208.3M |
| Cost and Expenses | 566.0M | 532.9M | 438.2M | 270.2M | 208.3M |
| Operating Income (EBIT) | (558.9M) | (532.9M) | (438.2M) | (270.2M) | (208.3M) |
| Non-Operating | |||||
| Interest Income | 19.0M | 25.3M | 24.7M | 24.9M | 7.6M |
| Interest Expense | — | — | — | — | 12.5M |
| Net Interest Income | 19.0M | 25.3M | 24.7M | 24.9M | (4.9M) |
| Other Non-Op Income/Expense | 20.0M | 27.5M | 25.2M | 11.4M | (2.7M) |
| Non-Operating Income (excl Interest) | (20.0M) | (27.5M) | (25.2M) | (11.4M) | (9.8M) |
| EBT (Pre-Tax Income) | (538.9M) | (505.4M) | (412.9M) | (258.8M) | (211.0M) |
| Income Tax Expense | (698.0K) | 215.0K | 891.0K | 567.0K | 9.0K |
| Bottom Line | |||||
| Net Income | (538.2M) | (505.6M) | (413.8M) | (259.3M) | (211.0M) |
| Earnings from Cont. Ops | (538.2M) | (505.6M) | (413.8M) | (259.3M) | (211.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (538.2M) | (505.6M) | (413.8M) | (259.3M) | (211.0M) |
| Per Share | |||||
| Basic EPS | ($2.82) | ($2.77) | ($2.73) | ($1.88) | ($1.71) |
| Diluted EPS | ($2.82) | ($2.77) | ($2.73) | ($1.88) | ($1.71) |
| Revenue Per Share | $0.03 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 205.5M | 182.4M | 151.6M | 138.1M | 123.1M |
| Diluted Shares Outstanding | 205.5M | 182.4M | 151.6M | 138.1M | 123.1M |
| Profitability Metrics | |||||
| EBITDA | (538.5M) | (505.0M) | (412.6M) | (258.5M) | (198.3M) |
| D&A | 394.0K | 409.0K | 377.0K | 231.0K | 193.0K |
| EBIT | (538.9M) | (505.4M) | (412.9M) | (258.8M) | (198.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026